{"id":"fe238faea49f","type":"article","url":"https://hartvaat.nl/2016/01/05/varenicline-voor-stoppen-met-roken-bij-patienten-opgenomen-met-acuut-coronair-sy/","title":"Varenicline voor stoppen met roken bij patiënten opgenomen met acuut coronair syndroom","title_en":"Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts"],"tags":["acuut-coronair-syndroom","roken","rosuvastatine"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.115.019634","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.115.019634","authors":["Mark J Eisenberg","Sarah B Windle","Nathalie Roy","Wayne Old","François R Grondin","Iqbal Bata","Ayman Iskander","Claude Lauzon","Nalin Srivastava","Adam Clarke","Daniel Cassavar","Danielle Dion","Herbert Haught","Shamir R Mehta","Jean-François Baril","Charles Lambert","Mina Madan","Beth L Abramson","Payam Dehghani"],"significance":6,"published":"2016-01-05","source_date":"2016-01-05","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/","https://hartvaat.nl/kennis/coronairlijden/ecg-bij-acs/"],"congress":"","summary_en":"This multicenter randomized trial showed that varenicline initiated during hospitalization for ACS significantly improves smoking cessation rates at 6 months, demonstrating the effectiveness of in-hospital smoking intervention.","created":"2026-07-03T10:25:51Z","updated":"2026-07-03T13:25:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Multicenter dubbelblinde RCT naar de effectiviteit van varenicline, gestart tijdens ziekenhuisopname, voor rookstop na een acuut coronair syndroom. De studie onderzoekt of vroege farmacologische interventie de abstinentie na ontslag kan verbeteren.","abstract_original":"BACKGROUND: Less than one-third of smokers hospitalized with an acute coronary syndrome (ACS) remain abstinent following discharge. We assessed whether varenicline, begun in-hospital, is efficacious for smoking cessation following ACS. METHODS AND RESULTS: We conducted a multi-center, double-blind, randomized, placebo-controlled trial in which smokers hospitalized with an ACS were randomized to varenicline or placebo for 12 weeks. All patients received low-intensity counseling. The primary end point was point-prevalence smoking abstinence assessed at 24 weeks by 7-day recall and biochemical validation using expired carbon monoxide. A total of 302 patients were randomized (mean age 55±9 years; 75% male; 56% ST-segment elevation myocardial infarction; 38% non-ST-segment elevation myocardial infarction; 6% unstable angina). Patients smoked a mean of 21±11 cigarettes/d at the time of hospitalization and had been smoking for a mean of 36±12 years. At 24 weeks, patients randomized to varenicline had significantly higher rates of smoking abstinence and reduction than patients randomized to placebo. Point-prevalence abstinence rates were 47.3% in the varenicline group and 32.5% in the placebo group (P=0.012; number needed to treat=6.8). Continuous abstinence rates were 35.8% and 25.8%, respectively (P=0.081; number needed to treat=10.0), and rates of reduction ≥50% in daily cigarette consumption were 67.4% and 55.6%, respectively (P=0.05; number needed to treat=8.5). Adverse event rates within 30 days of study drug discontinuation were similar between groups (serious adverse events: varenicline 11.9%, placebo 11.3%; major adverse cardiovascular events: varenicline 4.0%, placebo 4.6%). CONCLUSIONS: Varenicline, initiated in-hospital following ACS, is efficacious for smoking cessation. Future studies are needed to establish safety in these patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794573."}